Bordetella Pertussis Fimbriae (Fim2 and Fim3) Expression Evaluation in Different Stages of Cultivation to Produce Vaccine

Document Type : Original Article

Authors

1 MSc in of Microbiology.Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran.

2 Assistant Professor of Microbiology.Razi Vaccine and Serum Research Institute, Agricultural Research and Development Research Organization (AREEO), Karaj, Iran.

3 Assistant Professor of Microbiology.Department of Microbiology, Karaj Branch, Islamic Azad University, Karaj, Iran.

Abstract

Background and Objective: Fimbriae (Fim2 and Fim3) are one of the most important virulence factors in Bordetella pertussis and it causes the adhesion of bacteria to the upper respiratory tract cells and that enhances immune response. The level of antibody production against fimbriae is directly related to the level of protection. Fimbriae is one of the main components in both whole-cell and acellular pertussis vaccines. According to WHO standard, in the whole-cell vaccine, presence of fimbriae must be confirmed by two techniques including ELISA and slide agglutination.
Subjects and Methods: In this research, two strains of B. pertussis 509 (with Fim2) and 134 (with Fim3) were tested by culturing in B2 and presentation of fimbriae was assessed at different stages of cultivation. In this study indirect ELISA and slide agglutination assays were used to determine and evaluate the presence and quantity of the fimbriae during cultivation period. After confirming the presence of the fimbriae, two strains (134 and 509) were cultured in B2 medium; and according to the fimbriae expression, the best time for harvesting and stopping the cultivation was determined.
Results: The high level of fimbriae expression and the best time for harvesting and stopping the culture was in the log phase. However, the level of expression in two strains was dissimilar in different time points, but eventually the most expression level was in the log phase.
Conclusion: According to the results of the highest expression of Fim2 and Fim3, and the best time for bacterial removal of the bacterial logarithmic phase governor. Although the expressions of these two fimbriae differ in this phase, the ultimate fimbria presence is in this phase.

Keywords

References

1-Miller E, Vurdien JE, White JM. The epidemiology of pertussis in England and Wales. Communicable Disease Report Review. 1992; 2(13).
2-Heikkinen  E, Xing  K, Ölander  R, Hytönen  J, Viljanen  M, Mertsola  J,  Hecorresponding  Q. Bordetella pertussis isolates in Finland: Serotype and fimbrial expression. BMC Microbiol. 2008; 8(162).
3-Cherry J, et al. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998; 16(20) 1901-6.
4-Ashworth  L, et al. Agglutinogens and fimbriae of Bordetella pertussis. Tokai J Exp Clin Med. 1988; 13.
5-Robinson A, Irons L, Ashworth L. Pertussis vaccine: present status and future prospects. Vaccine 1985;3(1) 11-22.
6-Geuijen  CA,  et al. Identification and Characterization of Heparin Binding Regions of the Fim2 Subunit of Bordetella pertussis. Infect Immun. 1998; 66(5) 2256–2263.
7-Gorringe  AR,  Vaughan TE, Bordetella pertussis fimbriae (Fim): relevance for vaccines. Expert Rev Vaccines. 2014; 13(10) 1205–1214.
8-Alexander F, Matheson M, Fry  N, Labram  B, Gorring A. Antibody Response to Individual Bordetella pertussis Fimbrial Antigen Fim2 or Fim3 following Immunization with the Five- Component Acellular Pertussis Vaccine or to Pertussis Disease. Clin Vaccine Immunol. 2012; 19(11) 1776–1783.
9-Xu  Y,  Wang  Y, Tan  Y, Zhang H, Wu L, Wang L, Zhang  S. Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis. BMC Microbiology, 2009 9(274).
10-Chen  Q, et al , Novel architectural features of Bordetella pertussis fimbrial subunit promoters and their activation by the global virulence regulator BvgA. Mol Microbiol. 2010; 77(5) 1326-40.
11-Fazekas  A,  Steeves R, Newmaster S. Improving sequencing quality from PCR products containing long mononucleotide repeats. Biotechniques. 2010; 48(4) 277-85.
Jundishapur Scientific Medical Journal
Volume 16, Issue 3 - Serial Number 108
September and October 2017
Pages 345-354

Files

History

  • Receive Date: 04 April 2017
  • Revise Date: 11 July 2017
  • Accept Date: 19 July 2017

Share

How to cite

Statistics